- Home
- FOUR vs TLX Comparison
FOUR vs TLX Comparison
Compare FOUR & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOUR
- TLX
- Stock Information
- Founded
- FOUR 1999
- TLX 2015
- Country
- FOUR United States
- TLX Australia
- Employees
- FOUR N/A
- TLX N/A
- Industry
- FOUR Business Services
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- FOUR Consumer Discretionary
- TLX Health Care
- Exchange
- FOUR Nasdaq
- TLX Nasdaq
- Market Cap
- FOUR 6.9B
- TLX 5.7B
- IPO Year
- FOUR 2020
- TLX N/A
- Fundamental
- Price
- FOUR $90.88
- TLX $11.54
- Analyst Decision
- FOUR Buy
- TLX Strong Buy
- Analyst Count
- FOUR 21
- TLX 3
- Target Price
- FOUR $112.05
- TLX $22.33
- AVG Volume (30 Days)
- FOUR 2.4M
- TLX 90.0K
- Earning Date
- FOUR 08-05-2025
- TLX 01-01-0001
- Dividend Yield
- FOUR N/A
- TLX N/A
- EPS Growth
- FOUR 55.45
- TLX 798.14
- EPS
- FOUR 2.56
- TLX 0.09
- Revenue
- FOUR $3,610,700,000.00
- TLX $484,687,790.00
- Revenue This Year
- FOUR $23.94
- TLX N/A
- Revenue Next Year
- FOUR $22.02
- TLX N/A
- P/E Ratio
- FOUR $35.43
- TLX $128.96
- Revenue Growth
- FOUR 23.86
- TLX 55.85
- 52 Week Low
- FOUR $68.09
- TLX $10.70
- 52 Week High
- FOUR $127.50
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- FOUR 43.67
- TLX N/A
- Support Level
- FOUR $86.86
- TLX N/A
- Resistance Level
- FOUR $90.36
- TLX N/A
- Average True Range (ATR)
- FOUR 3.72
- TLX 0.00
- MACD
- FOUR -0.83
- TLX 0.00
- Stochastic Oscillator
- FOUR 37.75
- TLX 0.00
About FOUR Shift4 Payments Inc.
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.